Shree Ganesh Remedies Ltd
Incorporated in 1995, Shree Ganesh Remedies Ltd is a manufacturer of Pharmaceutical Drug Intermediates for API & Fine Chemicals[1]
- Market Cap ₹ 607 Cr.
- Current Price ₹ 473
- High / Low ₹ 855 / 381
- Stock P/E 33.6
- Book Value ₹ 120
- Dividend Yield 0.00 %
- ROCE 19.2 %
- ROE 17.0 %
- Face Value ₹ 10.0
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 35 | 64 | 49 | 126 | 109 | 101 | |
| 26 | 52 | 35 | 84 | 69 | 67 | |
| Operating Profit | 9 | 13 | 14 | 42 | 39 | 34 |
| OPM % | 25% | 20% | 28% | 33% | 36% | 33% |
| 1 | 4 | 2 | 3 | 4 | 4 | |
| Interest | 0 | 1 | 0 | 1 | 2 | 4 |
| Depreciation | 1 | 2 | 3 | 6 | 10 | 10 |
| Profit before tax | 9 | 14 | 13 | 38 | 31 | 24 |
| Tax % | 28% | 23% | 25% | 26% | 26% | |
| 6 | 10 | 10 | 28 | 23 | 18 | |
| EPS in Rs | 4.88 | 8.18 | 7.62 | 21.96 | 17.97 | 14.09 |
| Dividend Payout % | 18% | 13% | 18% | 2% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | % |
| TTM: | -17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | % |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 24% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 13 | 13 | 13 |
| Reserves | 25 | 33 | 109 | 132 | 141 |
| 1 | 4 | 36 | 38 | 38 | |
| 7 | 9 | 12 | 8 | 13 | |
| Total Liabilities | 41 | 55 | 171 | 192 | 204 |
| 14 | 20 | 81 | 95 | 105 | |
| CWIP | 0 | 0 | 17 | 9 | 9 |
| Investments | 4 | 3 | 5 | 18 | 19 |
| 23 | 32 | 69 | 70 | 71 | |
| Total Assets | 41 | 55 | 171 | 192 | 204 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -5 | 5 | 3 | 30 | 31 | |
| -0 | -3 | -1 | -33 | -35 | |
| -0 | -0 | -1 | 10 | -1 | |
| Net Cash Flow | -5 | 1 | 2 | 7 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 101 | 101 | 59 | 75 | |
| Inventory Days | 125 | 61 | 156 | 223 | |
| Days Payable | 75 | 43 | 51 | 61 | |
| Cash Conversion Cycle | 151 | 119 | 164 | 238 | |
| Working Capital Days | 145 | 103 | 89 | 111 | |
| ROCE % | 35% | 19% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 24 Jan
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
23 Jan - Q3FY26 revenue ₹21.11cr (-22%); PAT ₹3.10cr (-43%); 9MF revenue ₹76.09cr (-10%).
- Announcement under Regulation 30 (LODR)-Investor Presentation 23 Jan
-
Financial Results For Quarter And Nine Months Ended December 31, 2025
23 Jan - Board approved unaudited standalone and consolidated results for quarter/nine months ended December 31, 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting
23 Jan - Board approved unaudited standalone and consolidated results for quarter and nine months ended December 31, 2025, limited review enclosed.
Annual reports
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025Transcript PPT REC
-
Aug 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
-
Feb 2025TranscriptAI SummaryPPT
-
Nov 2024Transcript PPT
-
Aug 2024TranscriptAI SummaryPPT REC
-
May 2023TranscriptAI SummaryPPT
-
Mar 2021TranscriptAI SummaryPPT
Business Overview:[1]
SGRL is an ISO 14001 certified complex chemical manufacturer, specialising in pharmaceutical intermediates and speciality chemicals.